Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sangamo Therapeutics (SGMO) over the last 16 years, with Q3 2025 value amounting to $267000.0.

  • Sangamo Therapeutics' Gains from Investment Securities rose 3152.71% to $267000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 31743.59%. This contributed to the annual value of $1.0 million for FY2024, which is 3160.0% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Gains from Investment Securities stood at $267000.0 for Q3 2025, which was up 3152.71% from $420000.0 recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Gains from Investment Securities peaked at $7.4 million during Q4 2021, and registered a low of $79000.0 during Q2 2024.
  • For the 5-year period, Sangamo Therapeutics' Gains from Investment Securities averaged around $945368.4, with its median value being $267000.0 (2025).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 101590.91% in 2021, then plummeted by 9808.88% in 2022.
  • Over the past 5 years, Sangamo Therapeutics' Gains from Investment Securities (Quarter) stood at $7.4 million in 2021, then plummeted by 98.09% to $142000.0 in 2022, then tumbled by 32.39% to $96000.0 in 2023, then soared by 256.25% to $342000.0 in 2024, then fell by 21.93% to $267000.0 in 2025.
  • Its last three reported values are $267000.0 in Q3 2025, $420000.0 for Q2 2025, and $2.2 million during Q1 2025.